Biotest Aktiengesellschaft provided earnings guidance for the full year 2020. The company is very confident that the sales in 2020 will be 10% higher than in 2019, and that despite the additional efforts in those COVID R&D projects, should be able to limit the loss due to this investment, such investment in P&L, to a minus EUR 10 million as EBIT figure, which was always in guidance.